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Mice lacking the adaptor protein that initiates an antiviral response down-
stream of the RNA helicases retinoic acid–inducible gene I (RIG-I) and mela-
noma differentiation-associated gene 5 (MDA5) have recently been described. 
These studies highlight the essential and nonredundant role of nucleic acid 
recognition in the induction of type I interferon production and raise impor-
tant questions regarding the nature of cell-autonomous virus detection in 
coordinating the antiviral response.
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Viruses are the most abundant patho-
gens on earth, and the survival of many 
organisms depends on their ability to 
sense and restrict viral infection. Detec-
tion of nucleic acids is a fundamental 
means of viral recognition in both pro-
karyotes and eukaryotes, although the 
types of receptors that recognize nucleic 
acids and the responses induced by these 
receptors vary greatly across phyla. In 
jawed vertebrates, nucleic acid–sensing 
receptors induce the production of 
type I interferons (IFNs). These cyto-
kines, originally identifi  ed as a soluble 
activity that blocked virus spread among 
cultured cells (1, 2), have several essen-
tial functions in the antiviral response. 
Type I IFNs act in both an autocrine 
and paracrine fashion by inducing the 
expression of hundreds of genes that 
together establish an “antiviral state,” 
which restricts the spread of virus among 
neighboring cells. In addition, type I 
IFNs enhance the function of natural 
killer (NK) cells and the diff  erentiation 
of virus-specifi   c cytotoxic T lympho-
cytes (CTLs), both of which recognize 
and eliminate virus-infected cells.
Despite the attention that type I 
IFNs have received since their identi-
fi  cation, the receptors that trigger their 
production remained mysterious until 
quite recently. Two types of receptors 
are now known to link pathogen de-
tection to the type I IFN response. The 
fi  rst type is Toll-like receptors (TLRs), 
which are expressed primarily by mac-
rophages and dendritic cells (DCs) (for 
review see reference 3). Several features 
of TLR-mediated nucleic acid recog-
nition indicate that these receptors are 
only part of the overall antiviral re-
sponse. First, TLRs specifi  c for viral nu-
cleic acids are expressed by only a small 
fraction of specialized cells, whereas 
almost all cells produce type I IFNs 
when infected with virus or transfected 
with nucleic acids. Second, the TLRs 
that sense nucleic acids are localized in 
the endosomes of sentinel cells that are 
generally not infected with virus. These 
cells sample endocytosed material but 
do not detect the presence of intra-
cellular infection. Third, mice lacking 
the adaptor protein MyD88, which are 
unable to activate most TLR signaling 
pathways, are remarkably resistant to 
infection with several viruses (4). Thus, 
although TLRs can detect viral infec-
tion, a second, more widely expressed 
receptor system must signal the pres-
ence of virus from within all cells.
The missing link
Two years ago, Fujita and colleagues 
published a landmark study that sparked 
the current advances in our understand-
ing of antiviral immune responses (5). 
The group screened for cDNAs that 
could enhance the activation of an IFN 
regulatory factor 3 (IRF3) reporter after 
transfection with polyinosinic–poly-
cytidylic acid (poly I:C)—a synthetic 
double-stranded (ds)RNA polymer that 
potently induces the production of type 
I IFNs. Their screen turned up the 
  caspase-recruitment domain (CARD)–
containing cytosolic RNA helicase 
RIG-I and the closely related MDA5 
(5). Shortly afterward, Balachandran et al. 
demonstrated that the signaling pro-
teins Fas-associated via death domain 
(FADD) and receptor-interacting pro-
tein 1 (RIP1) were essential for the 
production of type I IFNs in response 
to infection with vesicular stomatitis 
  virus (VSV) and transfection with poly 
I:C (6). Another signaling protein, TNF 
  receptor–associated factor 3 (TRAF3), 
was also shown to be involved (7). 
But the link between the RNA heli-
cases and these signaling molecules 
  remained undefi  ned.
Less than a year ago, four groups in-
dependently identifi  ed this missing link 
as a CARD-containing adaptor protein, 
naming it IFN-β promoter stimulator-1 
(IPS-1) (8), mitochondrial antiviral 
signaling  protein (MAVS) (9), virus-
  induced signaling adaptor (VISA) (10), 
and CARD adaptor–inducing IFN-β 
(CARDIF) (11). Here we refer to this 
protein as IPS-1. Overexpression of 
IPS-1 activated IRF3 and NF-κB, and 
knockdown of IPS-1 expression blocked 
signaling in response to both RNA 
  viruses and poly I:C. Interestingly, one 
group found that IPS-1 is localized to 
the outer membrane of mitochondria 
(9), and another group showed that it is 
cleaved and inactivated by the hepatitis 
C virus (HCV) protease NS3/4A (11), 
which had previously been shown to 
intercept dsRNA-activated signaling to 
IRF3 and IFN-β (12, 13).
Studies of mice lacking either RIG-I 
or MDA5 showed that the two heli-
cases are essential for type I IFN 
production in response to distinct classes 
of RNA virus. RIG-I responds to in 
vitro–transcribed dsRNA and is re-
quired for the in vivo response to VSV, 
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virus, and infl  uenza virus (14, 15). MDA5, 
by contrast, is the principal receptor for 
poly I:C and is essential for the antiviral 
response to the picornavirus encephalo-
myocarditis virus (EMCV) (15, 16).
Two recent studies, one in the 
July issue of the JEM and another in 
a recent issue of Immunity, reported 
that the phenotype of IPS-1–defi  cient 
mice is essentially the sum of the phe-
notypes of RIG-I and MDA5 single 
knockout mice (17, 18). In cells from 
IPS-1–  defi  cient mice, RNA virus– and 
dsRNA-induced signaling and type I 
IFN production were profoundly im-
paired. The only exception to this rule 
was in plasmacytoid (p)DCs, which ex-
clusively use TLRs to link RNA rec-
ognition to type I IFN production (14, 
18). IPS-1–defi  cient cells were unable 
to activate IRF3 and NF-κB, failed to 
produce type I IFNs and did not acti-
vate IFN-inducible genes downstream 
of RIG-I and MDA5 (17, 18). In vivo, 
Ips-1−/− mice were highly susceptible 
to infection with VSV (17, 18), despite 
normal serum levels of type I IFNs 
(probably induced by pDCs through 
TLR-dependent mechanisms) (18). 
  Interestingly,  Ips-1 was highly haplo-
insuffi   cient in vivo: heterozygous (Ips-
1+/−) and homozygous (Ips-1−/−) mice 
were equally susceptible to infection 
with VSV (18). Furthermore, as with 
MDA5 defi   ciency (15, 16), Ips-1−/− 
mice were more susceptible to lethal 
  infection with EMCV (17). Unlike VSV 
infection, however, EMCV infection 
failed to induce the early production 
of type I IFNs in the serum of IPS-1–
defi  cient mice, suggesting that this non-
enveloped picornavirus might evade 
TLR-dependent detection by pDCs.
These studies show that IPS-1 is es-
sential for antiviral responses to RNA 
viruses and synthetic dsRNA. In con-
trast, IPS-1 was not required for type I 
IFN production in response to trans-
fected DNA (17, 18), or to infection 
with the intracellular bacterium Listeria 
monocytogenes (18) or the Vaccinia pox-
virus (17). These data, together with 
recent reports demonstrating a TLR-
independent response to intracellular 
DNA (19–21), suggest that cytosolic 
RNA and DNA recognition activate 
the production of type I IFNs via dis-
tinct signaling pathways that converge 
on IRF3.
The characterization of IPS-1–
  defi  cient cells and mice is an important 
advance in our understanding of how 
cells respond to infection with RNA 
viruses. But these studies also raise in-
teresting questions regarding the nature 
of nucleic acid recognition and the dif-
ferent ways in which infected cells co-
ordinate antiviral immunity.
Are nucleic acids the sole initiators 
of antiviral type I IFN production?
The phenotype of IPS-1–defi  cient cells 
formally demonstrates that RIG-I and 
MDA5 are the primary, nonredun-
dant sensors that link cytosolic dsRNA 
detection to the type I IFN response. 
  Before the characterization of RIG-I 
and MDA5, the IFN-inducible protein 
kinase R (PKR) had been thought to be 
important for the type I IFN response 
to dsRNA, because PKR-defi  cient 
cells and animals show reduced type I 
IFN production and are susceptible to 
infection with VSV (22). However, in 
light of the identifi  cation of the RNA 
helicase pathway of viral recognition, it 
now appears that PKR does not induce 
the type I IFN response to cytosolic 
dsRNA. Instead, PKR appears to have 
a separate, but still important, role in 
cell-autonomous control of viral infec-
tion. The function of PKR most likely 
involves its ability to inhibit translation 
of host cell mRNA by phosphorylating 
the translation initiation factor eIF2α—
the only known substrate of PKR (22). 
Perhaps the reduced type I IFN pro-
duction by PKR-defi  cient cells refl  ects 
the possibility that type I IFNs are more 
effi     ciently translated under conditions 
where eIF2α is limiting, as would oc-
cur during viral infection.
Not only do these fi  ndings clarify 
the relative contribution of PKR to 
the antiviral response, they also imply a 
more general principle with fundamen-
tal implications for antiviral responses 
and autoimmunity: nucleic acid recog-
nition might be the only way for most 
cells to induce type I IFN production. 
In models of infection with various 
classes of RNA virus, IPS-1–defi  cient 
cells are completely unable to mount a 
type I IFN response. This suggests that 
no component of these viruses other 
than the RNA, including envelope 
glycoproteins and capsid proteins, can 
induce the production of type I IFNs. 
Moreover, it indicates that stress re-
sponses, which are activated in cells sup-
porting rapid viral replication, are also 
insuffi     cient to induce the production 
of type I IFNs. In this regard, it would 
be interesting to examine mitogen-
  activated protein kinase activity during 
viral infection in IPS-1–defi  cient cells, 
as it is likely that intact stress response 
pathways are activating the expression 
of genes other than type I IFNs.
If nucleic acid recognition is the 
only way for most cells to induce the 
production of type I IFNs in response 
to infection with RNA viruses, does a 
similar principle apply to recognition of 
DNA viruses? Until recently, dsRNA 
was thought to be the main signature of 
viral replication inside cells, produced 
by replicating RNA viruses and bidi-
rectional transcription of DNA viruses. 
However, the fi   nding that IPS-1–
  defi  cient cells mount a normal antiviral 
response to transfection with DNA, and 
to infection with L. monocytogenes or a 
poxvirus (17, 18), indicates that cyto-
solic dsRNA is not the only trigger of 
the type I IFN response. This raises the 
question of why two signaling pathways 
are needed to link nucleic acid detec-
tion to the antiviral response. The sim-
plest explanation is that RNA and DNA 
viruses activate diff  erent  cell-intrinsic 
eff   ector responses that are tailored to 
combating the particular type of virus. 
Importantly, neither type I IFNs nor ge-
neric IFN-inducible genes account for 
the specifi  city of this response, as trans-
fection with DNA and poly I:C acti-
vates a similar profi  le of IFN-inducible 
genes (21). Instead, the two signaling 
pathways might drive the transcription 
of distinct IFN-independent genes and 
might also activate diff  erent transcrip-
tion-independent antiviral mechanisms. 
If so, this would have important impli-
cations for the design of antiviral thera-
peutics, which would need to target the 
IFN-independent response appropriate 
for the type of virus infection.COMMENTARY
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Another implication of these studies 
relates to autoimmune disorders, which 
are often associated with the produc-
tion of type I IFNs (23). Most cells 
tested respond to RNA viruses and 
dsRNA in an IPS-1–dependent man-
ner, and a similarly ubiquitous response 
exists to cytosolic DNA (20, 21). Thus, 
an inappropriate response of these sen-
sor proteins to self-derived, intracellular 
nucleic acids might be a critical con-
tributor to autoimmunity. This scenario 
implies a cell-autonomous initiation of 
autoimmunity, which is distinct from 
several current models in which defec-
tive clearance of apoptotic cells results 
in the accumulation of extracellular nu-
cleic acids (24). TLRs might have a key 
role in the detection of these extracellu-
lar self-nucleic acids (25), particularly 
chromatin and RNA–protein com-
plexes (26–30), whereas the cytosolic 
RNA and DNA sensors might be re-
sponsible for a distinct set of autoim-
mune disorders that may only somtimes 
be associated with the failed clearance 
of apoptotic cells (19). Breeding IPS-1–
defi  cient mice with autoimmune-prone 
mouse strains would be a simple way to 
begin to address this hypothesis.
Cell-autonomous defense: beyond 
type I IFNs?
The observation that IPS-1–defi  cient 
mice are highly susceptible to infection 
with VSV despite generating a normal 
systemic type I IFN response (18) is 
reminiscent of the phenotype of FADD-
defi  cient fi  broblasts, which are unable 
to control VSV replication even after 
pretreatment with type I IFNs (6). It is 
possible that local concentrations of 
type I IFNs are too low to control viral 
replication in peripheral tissues in the 
absence of IPS-1. But there is another 
possible explanation that would suggest 
a role for IPS-1 signaling beyond the 
induction of type I IFNs: detection of 
cytosolic nucleic acids might trigger 
cell-intrinsic apoptosis and/or fl  ag the 
infected cells—but not their uninfected 
neighbors—for elimination by NK cells 
and CTLs.
One of the key functions of type 
I IFNs is to provide a paracrine alarm 
  signal and induce an antiviral state in 
uninfected neighboring cells. For ex-
ample, RIG-I and MDA5 are induced 
by type I IFNs, which then increase 
the sensitivity of nucleic acid detec-
tion in neighboring cells. Another key 
role of type I IFNs is to enhance the 
cytotoxic functions of NK cells and 
CD8+ T cells, which are important for 
inducing non–cell-autonomous apop-
tosis in infected cells. The recognition 
and elimination of infected cells must 
be carefully regulated such that only the 
infected cells—and not their immediate 
neighbors—are targeted. The IPS-1–
  dependent production of type I IFNs 
cannot supply the dominant “kill sig-
nal” for cytotoxic cells; this signal must 
be cell bound and it must be unique to 
infected cells (Fig. 1). Because RIG-I 
and MDA5 (and the currently unidenti-
fi  ed DNA sensor(s)) detect viral nucleic 
acids within infected cells, they are per-
fectly suited to induce surface expression 
of the ligands that uniquely fl  ag infected 
cells for   elimination. This induction 
must be IFN independent and could 
even be IRF3 independent (Fig. 1).
What might these ligands be? 
Promising candidates are ligands for 
activating and inhibitory receptors that 
are expressed by NK cells and cytotoxic 
CD8+ T cells (31). Coordinated down-
regulation of inhibitory ligands and 
up-regulation of activating ligands can 
determine the susceptibility of target cells 
to NK cell–mediated killing (31), but 
the mechanisms and signaling pathways 
responsible for altering the expression of 
these ligands remain largely unknown. 
These mechanisms must be cell autono-
mous, however, and could conceivably 
be controlled by IPS-1–  dependent sig-
nals in infected cells. One activating re-
ceptor expressed by NK cells and some 
eff  ector  CD8+ T cells is NKG2D, 
which recognizes cell surface ligands 
induced by various stresses, including 
viral infection (32). One prediction 
Figure 1.  Control of antiviral defense by IPS-1. (A) In normal cells infected with an RNA virus, 
IPS-1–dependent signaling activates type I IFNs, which turn on IFN-inducible genes in both infected 
cells and neighboring, uninfected cells. IPS-1 might also control cell-intrinsic apoptosis and the in-
duction of ligands for NK cells and CTLs, but only in infected cells. (B) In IPS-1–defi  cient cells, all four 
functions depicted in part A are lost and antiviral defenses are fully compromised. (C) Treatment of 
IPS-1-defi  cient cells with type I IFNs (either TLR-activated systemic IFNs or exogenous type I IFNs) 
only restores the IPS-1–independent response mediated by IFN-inducible genes.1840   IPS-1 IN ANTIVIRAL DEFENSE | Stetson and Medzhitov
of this model is that IPS-1–defi  cient 
mice would initiate adaptive immune 
responses normally after infection with 
RNA viruses but that eff  ector  CD8+ 
T cells and NK cells would be unable 
to kill infected cells. Another clinically 
relevant prediction is that treatment of 
virus-infected individuals with recom-
binant type I IFNs would only restore 
paracrine IPS-1–  dependent immune 
responses and not the cell-  autonomous 
eff  ector functions downstream of IPS-1 
(Fig. 1). For viruses such as HCV, which 
encodes the IPS-1–cleaving protease 
NS3/4A, pharmacological inhibitors 
that block NS3/4A would restore all 
functions of IPS-1 and would thus be 
far more eff  ective than treatment with 
type I IFNs alone (33).
IPS-1 might also control induction 
of cell-intrinsic apoptosis in an IFN-
independent manner (Fig. 1). Because 
IPS-1 is a transmembrane protein lo-
calized to mitochondria, it would be 
interesting to see if it interacts with or 
alters the function of the BCL2 family 
of proteins, which control mitochon-
dria-dependent apoptosis. However, 
infection with viruses other than VSV 
would be required to fi  rmly establish 
this, as VSV-infected cells can be killed 
by the strong cytopathic eff  ect of this 
virus, especially in the absence of type 
I IFN-induced signaling. Importantly, 
anchoring IPS-1 to other membranes 
in the cell impairs signaling, suggesting 
that mitochondrial localization, and not 
membrane attachment itself, is essential 
for its function (9). This observation, 
coupled with the fact that IPS-1 is not 
IFN inducible and is strongly haploin-
suffi   cient in vivo, implies that IPS-1 is 
coordinately regulated with the num-
bers of mitochondria and might be most 
abundant (and most sensitive to nucleic 
acid detection) in cells with the highest 
metabolic activity.
Conclusions and future directions
The description of IPS-1–defi  cient 
mice marks an important milestone in 
the rapidly advancing fi  eld of nucleic 
acid recognition. In just two years, the 
nonredundant cytosolic RNA sensors 
and several of the key signaling mole-
cules that link RNA recognition to the 
antiviral response have been identifi  ed 
and characterized in vitro and in knock-
out mice. Along the way, we have real-
ized that an entirely separate system 
exists for the detection of intracellular 
DNA that is likely to be important for 
host responses to DNA viruses and in-
tracellular bacteria. Together with the 
current knowledge of TLR-mediated 
nucleic acid recognition, we are now in 
a position to dissect the relative contri-
bution of all of these systems to immu-
nity and immunopathology.
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